SANTA ROSA, CA – February, 16, 2010 – Osseon Therapeutics Inc. today announced it has completed its first Osseoplasty™ procedures in Europe. The procedures were performed in Milan, Italy.
Teaming with its European distributor MBA Incorporado, SL, the largest independent medical device distributor in Europe, Osseoplasty cases are also scheduled to begin in the next weeks in the United Kingdom, Germany and Spain.
Osseon’s product line features the Osseoflex™ (steerable and curvable needle) and Osseoperm™ (bone cement). These products combine to form a unique new procedure termed Osseoplasty to treat painful acute fractures of the vertebrae seen increasingly in older individuals with osteoporosis and osteometastatic injuries.
Osseoflex can access the entire vertebral body from a singular unipedicular percutaneous access point. The Osseoplasty system is unique for its delivery of optimal viscosity cement and precise cement placement through the highly maneuverable Osseoflex needle. The Osseoplasty procedure provides rapid stabilization of vertebral fractures and significant pain relief on the day of treatment.
MBA will distribute Osseon’s products to physicians and hospitals throughout the European Union, including the United Kingdom, Germany, Spain, Portugal, Italy, Greece, Austria, Switzerland, Scandinavia, Turkey and Germany.
According to John Stalcup, Ph.D., CEO of Osseon, “MBA has an excellent and long-established international reputation for marketing and distributing medical devices for independent innovators and an unparalleled reputation for customer service. The partnership between MBA and Osseon represents a major step forward in the expansion of Osseoplasty into the key markets of Europe.”
Osseon Therapeutics, Inc. focuses on bringing to market alternative minimally invasive treatments for degenerative bone and joint disease. Headquartered in Santa Rosa, CA, the company's groundbreaking technology and delivery system provides comparable or better efficacy and safety than other commercial solutions while offering significant advantages in efficiency and cost. By improving the treatment of compression fractures within the lower portion of the thoracic and the entire lumbar vertebral spine, Osseon offers alternative solutions to patients suffering from these maladies, as well as the physicians and medical facilities that treat them. Its first-generation products have received both FDA clearance and the CE Mark for product distribution in the United States and European Union. For more information, visit our web site at www.osseon.com.
Osseon is a registered trademark of Osseon Therapeutics, Inc.
CONTACT: Michael Bivens, Director of Business Development, Osseon Therapeutics, 707.636.5953, Michael.Bivens@osseon.com